Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Julphar
McKinsey
Mallinckrodt
Healthtrust
Cantor Fitzgerald
Queensland Health
Boehringer Ingelheim
Daiichi Sankyo

Generated: October 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,493,582

« Back to Dashboard

Summary for Patent: 9,493,582
Title:Alkylated cyclodextrin compositions and processes for preparing and using the same
Abstract: The present invention related to low-chloride alkylated cyclodextrin compositions, along with processes for preparing and using the same. The processes of the present invention provide alkylated cyclodextrins with low levels of drug-degrading agents and chloride.
Inventor(s): Antle; Vincent D. (Olathe, KS), Lopes; Alvaro (Loures, PT), Monteiro; Daniel (Loures, PT)
Assignee: Cydex Pharmaceuticals, Inc. (San Diego, CA)
Application Number:14/381,568
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,493,582
Patent Claim Types:
see list of patent claims
Use; Composition; Process; Formulation;

Drugs Protected by US Patent 9,493,582

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Melinta BAXDELA delafloxacin meglumine POWDER;INTRAVENOUS 208611-001 Jun 19, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Onyx Therap KYPROLIS carfilzomib POWDER;INTRAVENOUS 202714-003 Jun 7, 2018 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Onyx Therap KYPROLIS carfilzomib POWDER;INTRAVENOUS 202714-002 Jun 3, 2016 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Onyx Therap KYPROLIS carfilzomib POWDER;INTRAVENOUS 202714-001 Jul 20, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,493,582

PCT Information
PCT FiledFebruary 27, 2013PCT Application Number:PCT/US2013/028094
PCT Publication Date:September 06, 2013PCT Publication Number: WO2013/130666

International Family Members for US Patent 9,493,582

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013226073 ➤ Try a Free Trial
Australia 2016210707 ➤ Try a Free Trial
Canada 2865950 ➤ Try a Free Trial
China 104704007 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
McKinsey
Cantor Fitzgerald
Daiichi Sankyo
Julphar
UBS
Chinese Patent Office
Cerilliant
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.